COVID-19 has deeply affected everyday life and public health. Specifically, the biopharmaceutical industry has been impacted, with business continuity disruptions at a time of increased demand for healthcare solutions. With so much uncertainty, adaptation to change is critical, and working together in partnership to create alternative strategies is required.
Due to COVID-19 restrictions, SaudiVax, a manufacturer of vaccines and biopharmaceuticals in the Kingdom of Saudi Arabia, faced challenges in their project to deliver necessary infrastructure to combat the growing prevalence of infectious, preventable disease in the Middle East and North Africa. Cytiva leveraged a virtual factory acceptance test (FAT) as a solution for SaudiVax to remotely approve critical FAT results. With this innovative option, SaudiVax was able to advance their manufacturing plan and create new strategies for the future.